How many drugs treat Endometrial Ablation Adjunct?

Drug Landscape tracks 3 marketed treatments for Endometrial Ablation Adjunct (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/endometrial-ablation-adjunct.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Endometrial Ablation Adjunct — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endometrial Ablation Adjunct (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Endometrial Ablation Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zoladex	goserelin	Tersera	Gonadotropin Releasing Hormone Receptor Agonist	pituitary gonadotropin secretion	1989-01-01
Zoladex	GOSERELIN ACETATE	Tersera	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1989-01-01
Zoladex	Zoladex	University of Michigan Rogel Cancer Center		Gonadotropin-releasing hormone receptor, Lutropin-choriogonadotropic hormone receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Tersera · 2 drugs in Endometrial Ablation Adjunct
University of Michigan Rogel Cancer Center · 1 drug in Endometrial Ablation Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Endometrial Ablation Adjunct:

Cite this brief

Drug Landscape (2026). Endometrial Ablation Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/endometrial-ablation-adjunct. Accessed 2026-06-10.

Endometrial Ablation Adjunct full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing